Medexus Pharmaceuticals Inc (TSE:MDP) has released an update.
Medexus Pharmaceuticals announces that the FDA has accepted for review the resubmission of their New Drug Application for treosulfan, expecting a decision by October 30, 2024. Treosulfan, already successful in Canada, could significantly impact Medexus’s revenue if approved in the US. The company remains optimistic about treosulfan’s approval and its potential in the US market, reflecting its strong performance as a treatment in Europe and Canada.
For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.
